Abstract
Purpose: :
To determine the incidence of endophthalmitis associated with bevacizumab and ranibizumab intravitreal injections.
Methods: :
This is a retrospective study, completed at The Ohio State University Medical Center over a five-year study period. All charts that were associated with billing and diagnosis codes for intravitreal injections of bevacizumab, ranibizumab and endophthalmitis were identified. Incidence rates and clinical features of patients with endophthalmitis secondary to intravitreal injections were calculated and described accordingly.
Results: :
During a five year period, 4042 intravitreal bevacizumab and 1708 intravitreal ranibizumab injections were administered. Incidences of endophthalmitis secondary to bevacizumab and ranibizumab injections were noted to be 0.099% and 0% respectively. Three of the four patients with endophthalmitis secondary to bevacizumab were culture negative. The incidence of sterile endophthalmitis of bevacizumab was 0.074%. There were no cases of sterile endophthalmitis secondary to ranibizumab.
Conclusions: :
The incidence of sterile endophthalmitis related to bevacizumab is higher than the incidence of sterile endophthalmitis secondary to ranibizumab.
Keywords: endophthalmitis • injection